Katona et al. (2005) report data from 100 of those patients (74 SPMS and 26 PPMS), showing no effect on serum levels of IFN-γ, IL-10, IL-12 or CRP, or on frequency of circulating IFN-γ-expressing CD3+ T cells. This evidence concerns the gene IFNG and primary progressive multiple sclerosis.